COPENHAGEN Danish pharmaceutical group Lundbeck has won approval in the United States of its epilepsy drug, Sabril, to be used in children aged 10 years and older.
Lundbeck said in a statement on Monday the United States Food and Drug Administration (FDA) had approved Sabril as an add-on therapy for the treatment of refractory complex partial seizures in children who have inadequately responded to several other treatments.
(Reporting by Mette Fraende; editing by David Evans)
Major depression is increasingly recognized as a serious U.S. health problem. Experts are trying to identify at-risk children and adults and treat depression in its earliest stages.